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Executive Summary 
 
Antimicrobial resistance (AMR) is a global health security threat and the reliability 
of surveillance systems that provide accurate information is crucial. Through the use of 
quantitative and qualitative methodologies, the surveillance and monitoring process can 
provide a diagnosis of AMR within under-resourced settings in South Asia. A literature 
review within a scoping/narrative structure was conducted for this capstone in order to 
illustrate current deficiencies in AMR surveillance and monitoring for select countries in 
the South Asian region. This capstone project embraces the perspective that AMR 
surveillance is the first and most crucial step in illustrating the current burden and 
impact of this issue and informing change-inducing policies and interventions. The 
project is a global call to action on AMR surveillance in the developing world.  
It was found that there is a general lack of systematic data collection regarding 
AMR in the region, rendering it a neglected problem within many countries. The 
emergence of AMR in developing nations in South Asia is a symptom of substandard 
surveillance practices. Pathogens that are problematic in terms of resistance are not 
well represented through surveillance information. Resource-related constraints and 
sociocultural attitudes are also problematic in terms of antibiotic use. Antibiotic 
misuse/overuse are important determinants as they can create environmental pressure 
that causes resistant strains to emerge in both humans and animals. It is often difficult 
to measure AMR burden in developing countries, due to biases in reporting, testing 
methodologies, defective legislative practices, etc. 
The development of a global surveillance system that overarches local systems 
and increases coordination, cohesion, and comprehensiveness is recommended. The 
ultimate goal is to supplement the creation of a global strategy to mitigate AMR through 
the development of stronger surveillance systems and collaborative networks around 
the world. These approaches should aid with the creation of time-oriented, realistic, and 
visible change. The WHO report, in conjunction with this capstone project, is an 
important first step in highlighting the magnitude of the problem and moving towards 
addressing the visible gaps in AMR surveillance in South Asia and other resource-
limited settings. The lack of evidence should fuel further examination of this issue and 
increased discussion within global health policy and practice. 
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1.0 Introduction 
1.1   Background – What is Antimicrobial Resistance (AMR)? 
Antimicrobial resistance (AMR) can be defined as the process whereby microbes 
become less sensitive to drugs (i.e. antibiotics); resistance occurs when an antibiotic is 
no longer effective against infections caused by a particular microorganism (WHO, 
2015a). Infections that become resistant have negative effects on mortality, treatment 
costs, spread of diseases, duration of illness and society at large (Okeke et al., 2005a; 
Yalcin, 2003). These effects are intensified when resources are constrained in 
developing settings (WHO, 2014a). Although resistance is a natural phenomenon, it is 
exacerbated by a variety of external factors, including antibiotic misuse/overuse (Drlica 
and Perlin, 2011). Patient/provider ignorance, cultural biases, health system failures, 
lack of knowledge/education, and a lack of resources are among factors that can 
contribute to antibiotic misuse and AMR (Byarugaba et al., 2010). Not adhering to 
prescription instructions, self-medicating with antibiotics, and sharing are examples of 
antibiotic misuse (Radyowijati, 2014). In addition to personal attitudes/behaviours, 
antibiotic use in the food supply chain and interest-based marketing by the 
pharmaceutical industry can dictate AMR progression (Byarugaba et al., 2010). AMR 
can affect anyone but the following groups are especially susceptible: young children, 
the elderly, and those with weakened immune systems (PHAC, 2014). These findings 
have important implications for susceptible populations in resource-limited settings. 
Due to the dynamic nature of AMR and its dependence on a range of 
geographically and contextually varied factors, surveillance and monitoring of the issue 
becomes extremely important. Without adequate surveillance to monitor AMR levels 
and trends, treatment for resistance can become deficient. Without immediate 
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intervention, the spread of AMR can prove disastrous to the realm of infection treatment 
and modern medicine at large (WHO, 2014a). Slow progress of new antibiotic 
development, and limited resistance data also render it imperative to preserve current 
methods of treating infections and enhance understanding of AMR (Reardon, 2014; 
Appendix A; Fig. 4). Strong surveillance and monitoring systems can aid with these 
components and serve as a foundation for AMR-related public health practice. In an 
increasingly globalized world, the emergence and spread of resistance thus presents a 
major challenge. Of particular concern for this project is AMR surveillance in select 
developing countries in South Asia. 
 
1.2   Surveillance and Monitoring of AMR 
      1.2.1   The Surveillance and Monitoring Process 
 Surveillance and monitoring of diseases is defined as the systematic collection, 
analysis, and interpretation of health-related data; dissemination to policy-makers and 
other decision-makers is an important component of this process (WHO, 2015b). 
Surveillance ensures that health information is high in quality and is a useful tool for 
offering timely data that can be utilized to aid with disease prevention and treatment.  
Definitions of surveillance can vary at the local, national, regional, and/or international 
levels (Byarugaba et al., 2010). Surveillance systems can be narrow or broad-based, 
focusing on specific diseases/organisms or a broad range, respectively (Bax et al., 
2001). Due to the multidimensional nature of the surveillance process, variations within 
practices can be observed across the globe.  
Understanding the organization of public health systems is essential for 
effectively analyzing and monitoring health outcomes. Surveillance and monitoring, as 
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an applied method for assessing health, can aid with evaluating the extent of AMR. 
Local, national, regional, and global surveillance strategies rely on laboratory-based 
technical measurements (e.g. minimal inhibitory concentration – MIC) of resistance 
through the use of patient pathogenic isolates (Drlica and Perlin, 2011). These are 
important indicators for streamlining scientifically-based and targeted treatment 
strategies. Thus, Drlica and Perlin (2011) term surveillance the ‘first line of defense’ in 
preventing AMR. Surveillance results are reported back to the various stakeholders 
(physicians, infection-control experts, governmental agencies, academic sector, etc.) in 
order to provide a forewarning and direct future action (Drlica and Perlin, 2011).  
Surveillance covers a range of purposes, including identification of resistance 
outbreaks and their burden, informing public health interventions, and educating the 
medical/general community (Drlica and Perlin, 2011; WHO, 2014a). Surveillance is 
advantageous for preventing increased costs due to the emergence of AMR, reduced 
chance of resorting to new and expensive drug development, and avoiding longer 
rehabilitation for patients (Byarugaba et al., 2010). Surveillance data is also useful for 
monitoring medical drug regimens and antibiotic sales, directing drug supplies, and 
producing context-appropriate infection control strategies (Byarugaba et al., 2010).  
 Strong surveillance systems are accurate, reliable, flexible, and timely; they 
should be able to efficiently pinpoint and report changes in antimicrobial susceptibility 
(Bax et al., 2001). They would also be able to recognize the various factors (e.g. social, 
political, scientific, economic, etc.) that inherently affect AMR data. Adaptability to the 
changing AMR landscape is beneficial if surveillance systems are specifically tailored to 
the environments in which they operate. In relation to this, Drlica and Perlin (2011) 
outline several key questions to ask of any surveillance system: 1) Are the patient 
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samples representative in terms of disease severity and resistance prevalence? 2) Are 
definitions of patient populations and methods within diagnostic laboratories 
standardized? 3) Is the data comparable across regions? 4) Are surveillance results 
relevant for community (in addition to hospital) settings? 5) Is the surveillance biased 
due to the source of funding? These are significant points of inquiry as poor surveillance 
can have numerous negative consequences. The WHO global report on AMR 
surveillance as well as other literature cited in this capstone highlight these gaps within 
South Asia and other developing settings.  
 
      1.2.2   2014 WHO Antimicrobial Resistance Global Report on Surveillance 
 The 2014 WHO Antimicrobial Resistance Global Report on Surveillance stems 
from the need for more advanced surveillance of AMR patterns and trends. Some 
current observations on the fundamental gaps in surveillance include unstandardized 
methodologies/data sharing and an absence of coordination/harmonization (WHO, 
2014a). Specifically, underreporting of data and a lack of a global strategy leads to 
biases in data collection that tend to over-represent outbreaks and severe hospital-
based infection cases, for example (WHO, 2014a). The report places emphasis on the 
need for greater surveillance of community-acquired infections as well as the 
development of robust national databases. Issues of timely dissemination and 
comparability of information, as well as the capacity of existing surveillance structures 
(e.g. precision of pathogenic testing) are also brought to the forefront (WHO, 2014a). 
These findings prioritize the need for enhancement of country-level AMR surveillance 
data from regions such as South Asia.  
As the WHO (2014a) states, resource-related constraints such as cost barriers  
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can prevent the use of expensive last-resort antimicrobial agents (i.e. carbapenems). 
The cycle of resistance continues whereby AMR levels increase and strategies to 
contain the issue become limited. The lack of data on AMR impact and high levels of 
antibiotic misuse accelerate the problem. Poor quality surveillance in settings with high 
infection rates is a major barrier to defining AMR burden (WHO, 2014a). For example, 
global data on gonorrhea resistance is lacking in reliability and antimalarial drug efficacy 
needs to be increasingly monitored (WHO, 2014a). Stronger surveillance will give heed 
to better estimation of the wider societal impact of such challenges.  
In this report, the WHO proposes the development of a global surveillance 
system that would improve AMR data availability and quality. A supplementary strategy 
is the development of an AMR global action plan (WHO, 2014b). In order to effectively 
identify and classify global burdens, standardized tools and increased collaboration are 
necessary. The WHO (2014a) asserts the need for multisectoral/integrated surveillance 
as well as an enhancement of strategies to assess the socioeconomic impacts of AMR. 
Okeke et al. (2005b) summarize some of the WHO’s key strategies for the containment 
of AMR, including a strengthening of global surveillance (Appendix B; Table 4). With 
regards to the data presented in this report, the WHO (2014a) emphasizes caution in 
interpreting the results, as various national/regional biases (e.g. lack of quality 
assurance/representativeness) may affect the quality of AMR data. Nonetheless, the 
report should be utilized as a tool for further development in this area (WHO, 2014a). 
 
      1.2.3   AMR, Animal Health, and Surveillance 
 In comparison to medical use, antibiotic use for the industrial production of food 
animals is disproportionately high (Drlica and Perlin, 2011). As such, increased 
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therapeutic guiding practices within health and agricultural sectors are essential for 
promoting sustainable antibiotic treatments, reduced AMR rates and improved human 
and animal health. A general lack of data availability for antimicrobial use in food 
animals hinders surveillance capacities for classifying resistance associations (Angulo 
et al., 2004). Assessing the development of resistance in the food chain is a beneficial 
multisectoral approach that allows for data sharing and comparability. Global 
surveillance systems that assess animal health, antibiotic use, and AMR rates and aid 
with appropriate interventions are necessary for pinpointing current trends.  
The WHO (2014a) suggests an integrated surveillance approach that 
incorporates tools/standards for cohesive analysis of AMR in food-producing animals 
and the supply chain to humans. In line with this, WHO has formed an alliance with the 
Food and Agriculture Organization of the United Nations (FAO) and the World 
Organisation for Animal Health (OIE) that promotes collaboration, coordination, 
capacity-building, advocacy, and policy development between the various sectors 
(WHO, 2014a). As part of managing non-human antimicrobial use, inconsistencies in 
surveillance methodologies and gaps in system design have been observed (WHO, 
2004). Weak legislations have also been ineffective at exercising control over the 
appropriate use of antibiotics within the animal sector in many countries (WHO, 2014c).  
The OIE is involved in numerous efforts that involve the development and 
enhancement of global standards/guidelines for animal health/veterinary 
services/laboratories, training for national systems, and assisted surveillance/data 
collection (WHO, 2014c). While surveillance of animal health can be complicated by 
differing species, priorities, and contexts, collaboration with the human health sector is 
emphasized in order to identify common pathogens of concern (WHO, 2014c). Clinical 
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management of animal infections should be appropriated through enhanced 
mechanisms for antibiotic approval and use (Simonsen et al., 2004). Rapid data sharing 
and interoperability between international surveillance systems is an important element 
of success for preventing AMR in animals and humans in South Asia and globally.  
 
1.3   The Situation in South Asia 
 South Asia, or the Indian subcontinent, is comprised of several developing 
countries that present tremendous health and economic burden in terms of AMR. 
Laxminarayan et al. (2013) point out the recent increase in sales of last-resort 
antibiotics in India and Pakistan. Consequentially, resistance to last-resort carbapenems 
can be seen in as many as ninety five percent of adults in India and Pakistan (Reardon, 
2014). Some primary developing world infections in humans that are the most 
influenced by AMR include tuberculosis, malaria, severe acute respiratory infections, 
and gram-negative bacteria induced sepsis (Vernet et al., 2014). As Byarugaba et al. 
(2010) point out, the burden of combined/multi-drug resistance is high in developing 
countries; these regions are also lacking in authentic and reliable surveillance data. 
Currently, case studies or point-prevalence assessments provide a large portion of 
resistance data in these settings; systematic surveillance systems are generally not in 
place (Okeke et al., 2005a). The lack of surveillance has made it difficult to retrieve 
comparable and quantifiable baseline data that can be used to develop and monitor 
AMR-related interventions (Okeke et al., 2005; Falagas & Karveli, 2006).  
Antibiotic usage in hospitals is high and community-acquired infections are one 
of the primary causes of mortality in these settings (Okeke et al., 2005a; Rosenthal et 
al., 2006). Ashley et al. (2011) analyzed the antibiotic susceptibility of various 
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pathogens from community-acquired infections in South Asian countries, finding high 
rates of antibiotic consumption and resistance in such areas. However, resistance 
reports from developing countries have variations in methods and quality of testing, 
which complicates the process of analysis (Ashley et al., 2011). Furthermore, poor 
laboratory diagnoses negatively affect the availability and reliability of AMR data (Ashley 
et al., 2011). In response to this, the authors emphasize the urgent need for improved 
laboratory methods and surveillance systems, in combination with increased 
centralization of information resources to improve documentation of community-
acquired infections in LMICs (Ashley et al., 2011). 
Selective pressure on certain antibiotics and abundant dissemination channels 
encourage the spread of resistance in developing areas (Okeke et al., 2005a). In 
addition to haphazard antibiotic use by patients and providers, a lack of human and 
financial resources is of concern in South Asia (Byarugaba et al., 2010). Deficiencies in 
isolate testing and the fact that treatment regimens are often based on clinical 
diagnoses instead of broader indications of resistance promote antibiotic overuse 
(Byarugaba et al., 2010; Reardon, 2014). Furthermore, surveillance is often not 
longitudinal in these regions; there is a lack of routine analysis of resistance patterns 
(Byarugaba et al., 2010). In South Asia, challenges in surveillance are due to many 
factors such as biases in reporting tactics, variations in study designs, variations in 
global bacterial strains, variations in patient populations and usage patterns, etc. 
(Byarugaba et al., 2010). These problems are often visible in developing countries and 
are exacerbated by an array of challenges linked to the scarcity of resources.  
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2.0   Project Purpose and Objectives 
 As Drlica and Perlin (2011, p. xv) warn,  
“Our failure to adequately address resistance problems may ultimately push the control 
of infectious disease back to the pre-penicillin era.” 
 
 
This capstone serves as a key point of discussion for current limitations in 
understanding and addressing AMR in developing settings. The primary purpose of this 
project is to examine the broad range of factors that influence AMR and analyze the role 
of surveillance and monitoring in recognizing these elements. The objective is to 
demonstrate how appropriate surveillance and monitoring systems can navigate AMR 
data and aid with reductions in prevalence and incidence. This will be primarily achieved 
through analysis of ground-level data from various countries in the Indian subcontinent, 
including India, Pakistan, Bangladesh, and Sri Lanka. These case studies will provide a 
point of comparison (as per WHO recommendations) that will shed light on the potential 
link between resource scarcity and increased negative effects of AMR. The primary aim 
is to identify and assess existing needs in the health and surveillance systems of these 
countries in order to promote improvement in performance. An evidence-based 
approach will be utilized to answer the following question: What are the current gaps 
that exist in AMR surveillance in South Asia and how can these inform future practice-
based recommendations for AMR mitigation?  
   
3.0   Methods 
The primary method for this project was a literature review that was conducted 
within a scoping/narrative structure in order to assess the magnitude of AMR and 
associated challenges in surveillance for the South Asia region. This review is an 
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attempt to scope/map out key concepts in the area of South Asian AMR surveillance 
and monitoring, while identifying gaps in the associated research. The final result is a 
summary of current literature on the topic that provides a narrative for understanding the 
complexities of AMR surveillance and monitoring. As part of these methods, a variety of 
data sources were consulted, mostly discovered through extensive searches on Google 
Scholar as well as specific electronic databases such as MEDLINE, PubMed Central, 
Web of Knowledge, Global Health (Ovid), and Web of Science. Through this systematic 
method, peer-reviewed journal articles were navigated by utilizing various combinations 
of the following indicators: resistance, antimicrobial resistance, AMR, antimicrobial drug 
resistance, antibacterial resistance, antibiotic resistance, antibiotic (use), (global) 
surveillance, monitoring, South Asia, India, Pakistan, Bangladesh, Sri Lanka, resource-
constrained, resource-limited, under-resourced, low and middle income, developing 
countr(ies), challenge(s), health, etc. The search strategy was comprised of selective 
input of indicators into database search functions in order to produce relevant results.  
The aim of the review was to find literature that encompassed surveillance of 
AMR in developing regions as a whole and areas of South Asia, specifically. Current 
status of South Asian surveillance was the key area of interest and determinant for data 
selection. Primary search results from several databases yielded broad-based clinical 
studies of specific pathogens and associated resistance. Literature on surveillance-
specific challenges and/or recommendations was limited. Overall, selection of journal 
articles was based on inclusion of discussion on AMR surveillance as the focal point. 
Information on South Asian surveillance systems was extracted from these articles for 
case-by-case analysis as well as for cross-country comparisons. Narrowing of search 
results to more specific research was also done through scanning of article reference 
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lists. In general, the majority of results covered AMR prevalence/incidence with notable 
gaps in information with regards to resource scarcity and AMR surveillance. 
 
4.0   Findings 
4.1   Overview of Search Results 
Overall, has been found that increased use of certain antimicrobial agents has 
led to increased levels of resistance in some parts of South Asia (Byarugaba et al., 
2010). This has placed immense burdens on disease-specific control programs that are 
in place within these countries (Byarugaba et al., 2010). AMR has greater 
consequences for developing countries and further weakens their health systems, 
leading to increased underdevelopment (Sirinavin & Dowell, 2004). Furthermore, the 
presence of resistance deteriorates health outcomes in these countries for previously 
treatable infections such as tuberculosis and malaria (Okeke et al., 2005a). 
Laxminarayan (2004) also points out the general inaccessibility of effective antimalarial 
drugs (e.g. artemisinin) in resource-constrained settings, which enlarges the issue. It is 
therefore evident that AMR presents a great concern for the region, highlighting the 
importance of starting with a top-down approach to resolve these problems.  
 In the South Asian region and for developing countries as a whole, there is a 
substantial lack of specific literature on AMR surveillance. Literature searches yielded 
primarily clinical studies that examined the scientific nature of AMR in this region; 
country-specific data was also not readily available. From these findings, one can make 
the assumption that AMR surveillance is not prioritized in these countries. For 
developing settings, there are a variety of other issues internal and external to the 
health sector that can take precedence. For example, developing countries often lack a 
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cohesive framework for collecting/interpreting data for surveillance purposes, which puts 
the success of infection control at risk. Often, passive surveillance techniques are 
utilized, which may result in biased populations and/or samples (Byarugaba et al., 
2010). Methodological difficulties such as a lack of international reporting (due to 
unpublished work) and differing testing methods/quality assurance protocols can lead to 
serious deficits in AMR data (Byarugaba et al., 2010). Furthermore, noncompliance with 
study design guidelines is also problematic in these regions (Byarugaba et al., 2010). 
National resistance data is generally unavailable in South Asia for bacteria of 
public health importance, as evidenced by the WHO (2014a; Appendix B; Table 2). In 
India, for example, requested national resistance data for select bacteria-antibacterial 
drug combinations was not available (WHO, 2014a). Systematic multi-centre 
collaboration is not present in these countries; microbiological cultures that are valuable 
tools for strong surveillance are not high in quality (Byarugaba et al., 2010). External 
factors such as a lack of resources/funding, as well as the political climate, play a role in 
determining these challenges (Byarugaba et al., 2010). Governmental bodies are often 
focused on providing quick and short-term solutions to health problems in developing 
countries; long-term data collection and surveillance planning are not prioritized 
(Byarugaba et al., 2010). Koplan (2001) points out that the lack of surveillance system 
presence in developing countries is also related to increased expenditure of resources 
on other new diseases and related potential threats of bioterrorism.  
 Limited funding for conducting surveillance studies has negative impacts on the 
extent and quality of pathogenic testing in the developing world (Byarugaba et al., 
2010). Antibacterial susceptibility testing (AST) tests the susceptibility of infectious 
microbes to various antibiotics (Drlica and Perlin, 2011). This is achieved through 
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collecting isolates, exposing them to a variety of antibacterial agents, and analyzing the 
results through the use of commercial microbial analysis systems (Drlica and Perlin, 
2011). A lack of resources often means that optimal testing methods are not utilized; 
limited budgets influence the use of traditional methodologies (e.g. disk diffusion tests) 
rather than testing for MICs (Byarugaba et al., 2010). In line with this, the health sector 
is often not prioritized in terms of resource allocation, which ultimately affects the 
development of national surveillance programs (Vaughan & Walt, 1984). Weak 
infrastructure and fractured health care capacities provide further detriment. As a result, 
quality assurance and the availability of comparable data are hindered. 
Byarugaba et al. (2010) utilize the term ‘microbiological gap’ to refer to local 
laboratories within developing countries that are not exhibiting optimal functioning 
and/or training with regards to AMR. Archibald and Reller (2001) attribute these 
challenges to widely held perceptions that encourage the idea that AMR is not a major 
health problem. Furthermore, a lack of communication between laboratory technicians 
and physicians adds to the issue in these countries (Archibald & Reller, 2001). With 
reference to the microbiological gap, Byarugaba et al. (2010) point to the need for 
increased quality assurance and resource management for appropriate analysis of 
patient samples and surveillance reporting. Use of expensive technologies for 
bacteriological analysis presents a challenge for resource-constrained settings, where 
skewed priorities and costly AST limits the amount of surveillance reporting (WHO, 
2014a). Furthermore, incomplete reporting that is fueled by flawed data storage 
practices contributes to the observed challenges (Byarugaba et al., 2010). Deficiencies 
in laboratory capacities such as supply-chain issues, inadequate culture preparations, 
and insufficient harmonization of methods are other contributors (Vernet et al., 2014).  
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Regulatory practices are often less than substantial and increase the use of 
antibiotics and thus resistance in developing countries (Byarugaba et al., 2010). 
Although legislations surrounding antibiotic use may exist, enforcement is weak and is 
further complicated by social factors such as poverty, war, and other types of human 
conflicts (Byarugaba et al., 2010; Mitema, 2010). A lack of regulatory bodies in 
developing countries highlights the need for appropriate leadership/governance and 
collaboration with regards to the control of prescription practices as well (WHO, 2001). 
Developing settings often serve as ‘breeding grounds’ for AMR development, which is 
further disturbed by the absence of appropriate guidelines (Byarugaba et al., 2010).  
A lack of structure that promotes appropriate infection control guidelines results 
in an environment that is not cohesive in terms of public health action. Sirinavin and 
Dowell (2004) relay that unstructured and under-resourced settings are often prone to 
ineffective infection control strategies (e.g. insufficient hand washing) and/or leadership 
with regards to AMR. As Byarugaba et al. (2010) note, weak health systems in 
developing countries (due to lack of staff, training, resources, etc.) lead to weaker 
infection control practices and thus increased rates of AMR in hospitals. It is also 
possible for the resistance to spread to the larger community through these means 
(Okeke et al., 2005a; 2005b). Although highly skilled workers and planners are present 
in most of these countries, medium-skilled workers that are needed in order to conduct 
relevant work are facing shortages (Byarugaba et al., 2010). Furthermore, rural to urban 
migration in most developing countries is a cause for concern; it is difficult to attract 
workers to rural communities where there is a high need for surveillance studies 
(Byarugaba et al., 2010). In line with this, worker motivation is often low, primarily due to 
the vertical hierarchy that results in limited opportunities (Byarugaba et al., 2010).   
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In LMICs, a lack of resources, combined with various markers of social location 
(e.g. age, gender, race, SES, etc.), can negatively affect health outcomes such as AMR. 
DiazGranados et al. (2008) effectively illustrate the impact of AMR according to various 
levels of resources, along with possible solutions to relevant problems (Appendix B; 
Table 6). For settings with moderate resource limitation, incomplete or inconsistent 
information/practices are of main concern (DiazGranados et al., 2008). It is a 
challenging feat to set up surveillance systems in resource-constrained settings, where 
there are major limitations in laboratory capacity, quality control, availability of reliable 
reagents, supervision, and staff training (Byarugaba et al., 2010). Other deficits include 
limited availability of demographic data, informational databases, and information 
dissemination channels (Byarugaba et al., 2010).  
Comparatively, it is evident that resistance data sourcing from developing 
countries is not on par with strong surveillance system requirements. Unavailability, 
non-representativeness, and inaccuracy of data are some current challenges that affect 
the quality of AMR surveillance in South Asia (Byarugaba et al., 2010). Inadequate 
diagnostics can also lead to delayed detection of AMR as health care providers assume 
their duties without appropriate knowledge of susceptibility patterns (due to weak 
surveillance) (Byarugaba et al., 2010). Prescribers often base clinical diagnoses on 
solely the strength of the patients’ symptoms, often disregarding important diagnostic 
tools (Okeke et al., 2005b). In line with this, laboratories in resource-constrained 
settings will often change protocols and/or create their own, which poses a serious 
problem (Okeke et al., 2005b). These resource-dependent capacities form the basis of 
strong surveillance and are essential targets for intervention in these countries.  
On an individual level, the data reveals that the ‘diversity in readership’ of  
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antibiotics across geographic settings is a challenge (Drlica and Perlin, 2011). This 
means that varying interpretations of appropriate antibiotic use and their potential 
effects are hindering efforts to reduce AMR in regions such as South Asia. In order to 
change attitudes and practices, interventions in South Asia must be targeted to the 
relevant contributors (e.g. lack of knowledge, personal behaviours, misconceptions, 
traditional practices, etc.). Potentially harmful practices such as self-medication are 
enabled through ease of antibiotic accessibility through non-prescription means and a 
lack of enforcement (Drlica and Perlin, 2011). This creates a ‘culture of nonchalance’ 
towards antibiotic use (Drlica and Perlin, 2011), which has important implications for 
controlling misuse/overuse. High availability of counterfeit drugs (which is a common 
symptom of drug development in under-resourced countries) may further increase AMR 
through treatment failures (Hadi et al., 2006). Financial gain through sale of counterfeits 
is often prioritized over drug quality in such areas (Byarugaba et al., 2010). 
 Tupasi (1999) notes the emergence of resistance to quinolone-based antibiotics 
in the developing world, alluding to sociocultural attitudes and deficient economic 
policies as the causes. Sirinavin and Dowell (2004) point out that individual perceptions 
of antibiotics in developing countries deem them to be the stronger or more ‘powerful’ 
drugs, which inhibit rational use. Attitudes also revolve around the idea that 
antimicrobial agents should be able to ‘fix’ most problems, even if they may not be 
infection-related conditions (WHO, 2001; Sirinavin & Dowell, 2004). Another 
perspective-driven issue that poses a problem is the commonly held notion that new 
and costly drugs are more effective than pre-existing ones (WHO, 2001). Ideas such as 
these tend to affect prescription, dispensing, and utilization rates (increased use of new 
types) of antibiotics (Hadi et al., 2006). The cost of antibiotic use seems small on an  
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individual level but has wider consequences on a community level in South Asia. 
The behaviours of health care providers are influenced by financial gains (e.g. 
through antibiotic prescription sales/pharmaceutical referrals), which increase rates of 
irrational antibiotic prescription in South Asia (WHO, 2001; Sirinavin & Dowell, 2004). 
The same can be said for pharmaceutical companies, where the use of newer and 
costlier antibiotics results in profit (WHO, 2001). The current lack of training among 
health providers with regards to appropriate treatment methods only magnifies the issue 
(WHO, 2001). These systems-oriented factors within developing countries need to be 
more carefully scrutinized and monitored. In relation to this, Finch et al. (2004) point to 
the need for educational interventions for health care providers that currently use 
outdated information in these countries; a lack of continuing education directly affects 
antibiotic use. These factors, in confluence with weak surveillance systems, deem the 
management of AMR a challenging task in developing countries.  
 A lack of resources can reduce the capacity of health systems. In this case, gaps 
in data availability can point to issues in national health system functionality. These 
factors may lay evidence to additional constraints within LMIC health systems, including 
patient sampling difficulties (e.g. low sample sizes) and deficiencies in national 
accumulation and summation of laboratory data (WHO, 2014a). Data on resistance to 
third-generation cephalosporins in the Escherichia coli pathogen, for example, indicates 
that limited sampling is an issue in South Asian countries (WHO, 2014a). Considering 
the high burden of these infections, there also are gaps in South Asia for surveillance 
knowledge of Streptococcus pneumoniae and its susceptibility, pointing to the need for 
increased laboratory capacity and AST (WHO, 2014a). In relation to this, Sirinavin and 
Dowell (2004) found that there is often a lack of diagnostic testing that accompanies 
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health service delivery in resource-constrained settings. As such, the lack of a clinical 
base for medical practice often leads to overprescription and overuse of antibiotics 
(Sirinavin and Dowell, 2004). Therefore, potential gaps in knowledge and/or operational 
systems have serious implications for the quality of surveillance in these regions.  
Informational gaps, including pathogen definitions, also need to be more clearly 
addressed so that disease burden can be appropriately estimated. For example, it was 
found by the WHO (2014a) that nontyphoidal Salmonella disease burden is high in 
South Asia but the largest information gaps with regards to its resistance occur in the 
same region. Byarugaba et al. (2010) also assert that resource-constrained settings 
often lack patient and public-friendly informational resources on heath-related issues. In 
general, it is evident that large gaps in knowledge and high disease burdens occur 
simultaneously in developing countries. Critical evaluation of such aspects can 
strengthen surveillance capabilities and overall effectiveness. With this information in 
mind, public health professionals and stakeholders from other sectors should be wary of 
the fine balance that will be required to address the visible gaps.  
 
4.2   Case Study: India 
With regards to AMR, multidrug-resistant tuberculosis (MDR-TB) rates are high in 
India (especially among those who were previously treated) and treatment for the 
disease is generally limited (WHO, 2014a; Prasad, 2005). There are several factors that 
contribute to this shortfall, including insufficient training of staff, limited facilities for 
treatment/monitoring, and overall lack of coordination in programming (WHO, 2014a). 
Salmonella infections are also prevalent in India (Parry, 2003). Mathai et al. (2008) point 
out that there is also major multi-drug resistance amongst E. coli strains in rural and 
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urban areas of Southern India. Prevalence rates are often higher for urban areas due to 
the availability of antibiotics and poor sanitary conditions that harbor pathogens (Hart & 
Kariuki, 1998). Similarly, Ochiai et al. (2008) found that annual incidence of typhoid in 
India is relatively high (approximately 493.5 per 100,000 population) and there is visible 
multi-drug resistance amongst these isolates. Uneven methodologies, differences in 
health-seeking behaviours, and inappropriate use of antibiotics (e.g. fluoroquinolones) 
could be potentially contributing factors (Ochiai et al., 2008; Kumar et al., 2007). 
Although the emergence of typhoid-related resistance has been well characterized 
(Nath et al., 2000; Mirza et al., 1996; Okeke et al., 2005a) in the Indian subcontinent, 
surveillance-oriented interventions to combat these infections must be prioritized.  
Holloway et al. (2011) conducted several pilot projects in India, finding high AMR 
rates for various pathogens. The authors also found methodological issues with 
obtaining isolates and thus difficulties with data comparability. Logistical challenges for 
long-term surveillance activities were highlighted through this study; challenges with 
testing, sample size, data standardization, and data collection/management were 
echoed in the results (Holloway et al., 2011). The authors recommend enhancements in 
multidisciplinary capacity to produce more uniform AMR data in India (Holloway et al., 
2011). Similarly, a high prevalence of gram-negative bacterial infections and associated 
resistance has been found among travelers to India (Vernet et al., 2014). Use of 
fluoroquinolones in poultry is another contributing factor for antimicrobial resistance that 
is acquired through the food supply chain in South Asia and other continents (WHO,  
1998). These findings have important implications for AMR surveillance and potentially 
controlled use of antibiotics in these regions. 
Within South Asia, India has been estimated to have the highest rates of HIV- 
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infected individuals, but results vary according to different studies and areas 
(Byarugaba et al., 2010; Kumarasamy et al., 2005). Greater surveillance of HIV drug 
resistance is urgently needed in developing settings (Walensky et al., 2007; WHO, 
2014a). Overall, patterns of resistance in India are varied. For example, some studies 
have found antiretroviral resistance among certain populations in India (Deshpande et 
al., 2004; Hira et al., 2004) while others have not (Balakrishnan et al., 2005; Eshleman 
et al., 2005). Uniformity in data collection, as part of the development of broader 
surveillance systems, is therefore encouraged in such countries to promote clearer 
data. The nature of antibiotic use also affects the type of data that is available in 
developing countries such as India. For instance, Morris et al. (2008) noted that 
influenza vaccine use is low in India, despite the prevalence of influenza (IBIS, 2002).  
 Candida species fungal infections are also abundant in India (Xess et al., 2007; 
Girish Kumar et al., 2006). Several global surveillance programs have targeted these 
types of infections but continued surveillance support is needed (Pfaller et al., 2007). 
Cholera is another prominent disease in several South Asian countries and outbreaks 
have been observed in India, Pakistan, and Bangladesh (Sack et al., 2004; Krishna et 
al., 2006; Okuda et al., 2007; Narang et al., 2008). Underreporting of cases is a cause 
for concern in these regions; enhanced surveillance can aid with addressing such 
challenges. India also exhibits high rates of resistant infections within its hospitals, 
which creates a high socioeconomic burden (Rosenthal et al., 2006; Yalcin, 2003).  
Within the context of antibiotic misuse and/or overuse, Ray et al. (2000) found 
that use of fluoroquinolones against N. gonorrhoeae pathogens produced resistance in 
New Delhi, India. Prevalence of penicillin-resistant N. gonorrhoeae infections is high in 
India (Bala et al., 2003); inability to afford expensive cephalosporins could be worsening 
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these conditions for patients. It has also been found that oral treatments for gonorrhea 
have not been effective in India and should be monitored through increased surveillance 
(Byarugaba et al., 2010). Intensive care units in several Indian hospitals also displayed 
very high rates of methicillin-resistant Staphylococcus aureus (MRSA) infections; 
potential contributing factors include the vulnerability of intensive care units as well as 
inappropriate antibiotic use (Mehta et al., 2007).  
Shukla et al. (2004) reported high rates of resistant pneumoniae infections in 
Indian tertiary care hospitals. Song et al. (2004) found similar results among penicillin-
resistant pneumoniae infections. Duttaroy and Mehta (2005) also provide evidence for 
resistance to these infections in Gujarat. There is also a high prevalence of shigellosis 
infections in Kolkata (Sur et al., 2004). Moreover, resistance to various Shigellae strains 
is prominent in Indian pediatric patients (Dutta et al., 2002). Furthermore, Manchanda 
and Bhalla (2006) reported resistance amongst antimicrobial agents used to treat 
bacterial meningitis. Although rates are high, anecdotal evidence of such patterns and 
questionable testing methodologies decrease the uniformity/accuracy of data, calling for 
increased epidemiological surveillance of resistance levels and trends in India.  
With regards to the social determinants of AMR, Vajpayee at al. (2007) found  
that patient expectations and satisfaction are key determinants for physicians’ 
prescribing behaviours in India (Vajpayee et al., 2007). Moreover, Dua et al. (1994) 
found that more than three thirds of patients rely on their prescriptions when 
determining which antibiotics to use, suggesting a strong influence. On a similar note, 
Singh and Raje (1996) discuss the influence of patient demands in relation to traditional 
healers in India and their antimicrobial dispensing practices. A lack of training, 
technology, and supervision, combined with patients’ perceptions about antibiotics, 
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results in inappropriate use of these agents (Singh and Raje, 1996). In essence, patient 
benefits outweigh population benefits in terms of antibiotic use in such regions, which is 
often detrimental for mitigating AMR rates.  
The vast availability of counterfeit drugs in India also deems it necessary to 
enforce stricter drug regulations (Raufu, 2003). In line with this, Dua et al. (1994) found 
that in Nagpur, lay networks have a large influence on patterns of antibiotic use. 
Individuals often rely on advice from friends and/or family in terms of infection treatment; 
traditions and cultures affect these practices. Often, antibiotics are acquired through 
non-prescribed means and the abundance of drug stores in India with varying practices 
makes it difficult to enforce legislations (Dua et al., 1994). Furthermore, it is not 
uncommon for pharmacy attendants to change prescriptions so that they are more 
affordable for the patients (Dua et al., 1994). Kotwani et al. (2012) note that there is a 
general lack of data on the behaviours of community attendants with regards to 
antibiotic use, making it difficult to implement relevant interventions. Some key 
determinants of antibiotic misuse by pharmacy attendants in New Delhi included 
commercial interests, overstock, and near-expiry of drugs (Kotwani et al., 2012).  
In India, the rise of the corporate healthcare industry has also jeopardized 
surveillance planning and implementation (Byarugaba et al., 2010). This has had 
serious consequences for potential resources that the Indian government could have 
utilized for conducting broad-scale surveillance studies (Byarugaba et al., 2010). 
Environmental concerns such as the release of antibiotics into wastewater are also 
prudent in terms of dissecting the pharmaceutical industry in India (Reardon, 2014). 
Insufficient use of public reporting methods, in addition to the general lack of national 
interventions and regulations, produce the observe effects (Byarugaba et al., 2010). In 
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line with this, electronic and print media coverage of AMR issues in India should align 
with the larger goal of increased antimicrobial stewardship (Byarugaba et al., 2010). 
 Ghafur et al. (2013) outline the multi-stakeholder meeting in Chennai that aims to 
develop a road map for India with regards to addressing the challenge of AMR. This is 
an important first step in creating a consensus on the issue and developing action plans 
that are based on the Indian perspective. The lack of a national AMR policy in India, in 
addition to non-compliance with recommendations, deems it necessary. In addition to a 
broader multisectoral approach, policies on rational drug use and curriculum changes in 
medical training are some of the proposed road map action items (Ghafur et al., 2013). 
Infection control teams, task forces, hospital accreditations, and microbiological 
enhancements are some other highlights (Ghafur et al., 2013; Appendix A; Fig. 5). 
Dissemination of information and supervision of usage remain key concerns for India 
(Sharma et al., 2005). The road map for tackling AMR in India should also address 
domains of practice such as over-the-counter antibiotic sales, in-hospital antibiotic use, 
and auditing of pharmaceutical services. Currently, working groups in India under the 
Global Antibiotic Resistance Partnership (GARP) promote actionable policy for LMICS 
that includes improved surveillance and rationalization of antibiotic use (GARP, 2011).  
 
4.3   Case Study: Pakistan 
Dispensing practices in Pakistan are leading to vast amounts of antibiotic 
overuse and misuse. For example, Bhutta and Balchin (1996) noted that despite the 
presence of some regulations on pharmacies, antibiotic dispensing is very high, usually 
based on demand. Attitudes towards antibiotics can be highly blasé in Pakistan. In 
addition, Sturm et al. (1997) attribute over-the-counter availability of antibiotics to high 
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rates of self-medication in Karachi. They also highlight note-worthy sociocultural 
attitudes in Pakistan such as the misplaced belief that any antimicrobial agent can treat 
respiratory tract infections. An additional community-based trigger for irrational use is 
the reliance of the population on drug dispensers for medical advice. As Byarugaba et 
al. (2010) state, drug dispensers are often not formally trained in these settings. 
Additionally, drug dispensers try to accommodate the patients’ resources and often 
bargain in order to make the sale (Byarugaba et al., 2010).  
Parry (2003) notes that resistance to Salmonella infections is common in 
Pakistan. AMR associated with cholera infections is also prominent (Sack et al., 2004). 
Javaid et al. (2008) also illustrate the high prevalence of MDR-TB in Pakistan. Sabir et 
al. (2004) analyzed the relationship between antibiotic use and E. coli infections, finding 
that fluoroquinolone use could lead to resistance. Similarly, Jabeen et al. (2006) 
reported resistance to N. gonorrhoeae resulting from inappropriate treatments. Okeke et 
al. (2005a) reference a study that demonstrated gradual decreases in antibiotic sales in 
Karachi, paired with reductions in multidrug-resistant S. typhi isolates, suggesting a 
possible link. AMR levels can be attributed to a variety of patient, provider, and 
governmental factors; social, cultural, and economic factors also play a role (Byarugaba 
et al., 2010; Appendix A; Fig. 2/3). Sabir et al. (2004) suggest increased surveillance of 
AMR for community-acquired infections, coupled with educational programs and the 
development of guidelines to address these factors in Pakistan.  
Resources that combat selective pressures due to hospital use, the lack of 
preventative practices, and drug supply issues are urgently needed (Safdar & Maki, 
2002). Rates of methicillin-resistant S. aureus infections are also prevalent and 
increasing in Pakistani hospitals (Perwaiz et al., 2007; Shabir et al., 2010); contributing 
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factors include defective infection control measures and hospital conditions that induce 
overcrowding. Similarly, Byarugaba et al. (2010) discuss an audit of a public sector 
hospital in Karachi that revealed substandard AMR containment strategies (e.g. poor 
hand washing), a lack of occupational safety measures, insufficient sanitary practices, 
and absent policies/training. Overall, Naeem et al. (2006) found high rates of hospital-
based antimicrobial resistant infections in Pakistan. In line with this, overprescribing of 
antibiotics was a direct result of limited laboratory facilities and/or a lack of funds to 
utilize these services (Nizami et al., 1996). Moreover, physicians’ antibiotic prescribing 
rates in hospitals were high for the treatment of childhood diarrhea, even when these 
antimicrobial agents may not have been needed (Nizami et al., 1996).  
The Pakistan Antimicrobial Resistance Network (PARN) is an example of 
collaboration and knowledge sharing in action. The network serves as a common 
medium for information collection/dissemination by health professionals (Byarugaba et 
al., 2010). Technicians/clinicians can utilize the network to improve surveillance 
practices and technological operations through standardized techniques (Byarugaba et 
al., 2010). Public-private partnerships and increased consultation with global experts 
can further the cause. Vernet et al. (2014) also suggest increased monitoring of 
neonatal infections and related health outcomes in Pakistan and other South Asian 
countries, as part of a broader strategy to contain AMR in the developing world.  
 
4.4   Case Study: Bangladesh 
Cholera is of concern in Bangladesh, where antibiotic use/misuse contribute to a 
large portion of such epidemics (Sack et al., 2004). Resistant shigellosis infections 
(Talukder et al., 2004) and resistant Salmonella and pneumonia infections (Parry, 2003; 
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Granat et al., 2007) remain causes of concern. Rahman et al. (2002) and Bhuiyan et al. 
(1999) also found intensifying gonorrhea resistance in Bangladesh. Currently, antibiotic 
use that stems from local pharmacies is quite abundant in developing countries. One 
study in Bangladesh found that ninety five percent of drugs that were utilized by 
participants over one month were supplied from local pharmacies (Okeke et al., 1999).  
In Bangladesh, Istúriz and Carbon (2000) estimate that approximately ninety 
percent of drugs can be sold without a prescription. Hadi et al. (2006) point out that 
developing countries such as Bangladesh can be notorious for non-prescribed antibiotic 
use. It was found through a survey conducted in a rural district that antibiotics were 
prescribed by medical practitioners to sixty percent of their patients (Hadi et al., 2006; 
Sirinavin & Dowell, 2004). Additionally, over one hundred thousand doses of antibiotics 
were dispensed by pharmacies in this region; an additional one hundred thousand 
doses were dispensed without prescriptions (Hadi et al., 2006; Sirinavin & Dowell, 
2004). In line with this, Guyon et al. (1994) highlight the knowledge gaps that exist with 
regards to drug prescribing practices in Bangladesh. For example, it was found that 
prescribing rates for metrozinadole, a drug that is often not recommended, were the 
same between medical doctors and their assistants (Guyon et al., 1994). Not only are 
suboptimal drugs being prescribed in developing countries, qualifications of prescribers 
and differences in levels of knowledge and/or training are not clear. This can create 
serious problems for rational drug use and thus complicate epidemiological surveillance. 
Chowdhury et al. (2004) found that out of ten brands of pediatric drugs that were 
sold in pharmacies in Bangladesh, seven were substandard. As Hanif et al. (1995) 
describe, counterfeit medicine has had serious health consequences for some 
populations in the past. Islam and Farah (2007) note the lack of adherence with regards 
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to medicinal drug promotion; up to thirty five percent of promotional drug pamphlets that 
were distributed to health care physicians contained inaccurate information (Islam & 
Farah, 2007). Uppal et al. (1993) found that primary care settings in Bangladesh and 
other South Asian countries prescribed antibiotics based primarily on their availability. 
The practice of overlooking the medical needs of patients in favour of antimicrobial 
availability is alarming. Increased surveillance would give way to better regulatory and 
legislative policies that could improve accessibility and prescribing practices.  
  
4.5   Case Study: Sri Lanka 
 Chaung et al. (2008) noted high rates of resistance to pathogens that cause 
typhoid fever in Sri Lanka. Corea et al. (2003) examined the extent of methicillin-
resistant Staphylococcus aureus infections in Sri Lanka. Their findings imply the need 
for comprehensive surveillance of AMR that incorporates the various determinants of 
health. Shigellosis epidemics have also occurred in Sri Lanka and other countries in the 
Indian subcontinent (Byarugaba et al., 2010). Song et al. (2004) report the high 
prevalence of penicillin-resistant S. pneumonia infections in the country. AMR is 
evidently prevalent in Sri Lanka, pointing to the need for increased surveillance. 
Wolffers (1987) studied dispensing practices within several pharmacies in 
Colombo. One of the deficiencies noted by the author included the dispensers’ general 
lack of knowledge about antimicrobial agents. It was noted that attendants paid more 
attention to pricing and sales instead of the medical effects of these drugs (Wolffers, 
1987). Furthermore, dispensers were highly reliant on physicians’ prescriptions to 
dictate their practices, suggesting possible knowledge gaps. In line with this, Wolffers 
(1987) discusses the heavy influence of the pharmaceutical industry on pharmacy 
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attendants; dispensers relied on pharmaceutical sales representatives for most of their 
knowledge about drugs. Observations such as these have important consequences for 
larger policy-making that covers appropriate antibiotic use and training. 
 
5.0   Discussion 
5.1   Current Gaps in AMR Surveillance and Monitoring 
AMR is competing with an array of issues within the global health agenda (WHO, 
2013). Prevalent gaps in AMR knowledge are the main concern in terms of regional and 
national sources for surveillance in the developing world (Appendix B; Table 1 provides 
summary data for each South Asian country analyzed in this project). Through the 
literature review, it was also found that a large portion of the data on this topic is 
outdated and it was generally difficult to obtain relevant literature that focused on AMR 
surveillance in developing settings. Furthermore, most approaches provide 
recommendations but not actionable items. It was found that despite discussions of 
possible areas of interventions, specific strategies were often not part of the analyses. 
Moreover, case studies generally focus on the clinical aspects of AMR; surveillance is 
not at the forefront within most literature. The key action for moving forward would be to 
refine proposed recommendations and provide practicable strategies for intervention.  
Lackluster regulation and enforcement of legislative laws are key issues for 
developing countries. Governmental and regulatory issues are contributing to the 
spread of AMR. Due to prevailing attitudes and tendencies that foster an environment in 
which antibiotics are frequently and inappropriately utilized, resistance is becoming an 
increasingly serious concern for this region. Use of antibiotics without prescriptions and 
demand-related pressures on physicians are some contributing factors. Once again, 
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appropriate surveillance of AMR and antibiotic use trends can provide ground for 
analysis of these deeper issues regarding patient-provider reliance and cultural biases.  
As Okeke et al. (2005b) note, health systems within developing countries are 
extremely varied in terms of structure, making the need for specific and context-
appropriate surveillance very apparent. Kunin et al. (1987) assert similar views, 
suggesting that the characteristics of medical systems need to be carefully dissected for 
each country, as patterns of antibiotic use vary so widely. Allegranzi et al. (2011) 
conducted a systematic review and meta-analysis of healthcare-associated infection 
data in developing countries, finding visible surveillance constraints. Sampling methods, 
susceptibility methodologies, and study design are also vastly varied among 
surveillance structures (Bax et al., 2001). Furthermore, deficits in testing protocols, 
quality assurance, and capacity-building are leading to fragmented data (WHO, 2012). 
Underreporting and resulting non-representativeness of data in the developing world are 
other prominent AMR surveillance issues (Allegranzi et al., 2011).  
As Bax et al. (2001) point out, appropriate funding for supporting surveillance 
systems is of concern. Despite growing and documented interest in improving 
surveillance, studies lack support (Bax et al., 2001). Masterton (2008) emphasizes the 
unaffordability of surveillance system development in resource-constrained countries; a 
lack of data fuels further uncertainties about AMR and an inability to take action on the 
issue. Selgelid et al. (2008) point out that deficits in health systems increase difficulties 
in combatting resistant strains such as MDR-TB if appropriate resources for diagnosis, 
treatment, and follow-up are limited. Furthermore, a lack of MDR-TB surveillance in 
South Asia limits data availability for these infections (Vernet et al., 2014). Globally, 
systems are often funded by sectors (e.g. pharmaceutical industries) that may not have 
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interests that fully align with reduced resistance. Greater utilization of international 
expertise, clinical evidence, and infection control practices are some strategies for multi-
faceted improvement (Allegranzi et al., 2011; Appendix B; Table 5).  
Furthermore, a ‘lack of stewardship’ for AMR prevention/treatment means that 
there has been no coherence or leadership that promotes collective action on the issue 
(Drlica and Perlin, 2011). Only until very recently did the WHO collaborate on a draft 
global action plan for AMR. The action plan emphasizes shared ownership and 
engagement through outlining priorities for action and guiding principles (WHO, 2014b). 
Technical consultation, multinational commitment, and interagency/cross-sectoral 
discussions are other components (WHO, 2014b). A strategic objective of the plan is to 
strengthen the evidence base through rapid generation of knowledge that can 
rationalize intervention strategies. Ensuring that surveillance systems and diagnostic 
tools remain current is an importance objective (WHO, 2014). Greater investment in 
research for developing settings should also aid surveillance practices therein. Although 
progress is being made in the right direction, there are still serious deficiencies in the 
global health agenda in terms of AMR. Moreover, uncontrolled use of antibiotics within 
community and agricultural practices has yet to be cohesively regulated (Drlica and 
Perlin, 2011). These are all potential areas of intervention that are not only applicable 
on a regional level in South Asia but also on a global scale.  
 
5.2   Alignment with the WHO Global Report 
 As Okeke et al. (2005b) point out, AMR-related recommendations by the WHO 
present a complex challenge when applied to developing countries and the intersection 
of such a multitude of contributing factors. Navigating drug resistance in resource-
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limited settings is a complex feat. Overall, findings from this capstone resonate with the 
WHO report. In terms of policy implications, more coordinated and timely surveillance 
systems would prove highly beneficial for targeting the issue of AMR. In addition, 
increased health policy surrounding health delivery (specifically antibiotic prescription) 
and rational antibiotic use would ensure relatively uniform, regulated, and cohesive 
practices. Legislations that enforce regular reporting of AMR rates should be 
increasingly mandated within developing countries, so as to ensure timely data 
collection and enhanced quality control. Additionally, enforcements surrounding the sale 
of antibiotics through non-prescription means can tackle some of the observable 
community-based challenges with regards to AMR. 
As Drlica and Perlin (2011) indicate, a shift in the current ‘antibiotic philosophy’ is 
needed in order to ensure appropriate dosage and treatment regimens in hospital 
settings. There is also no standardization of surveillance systems in these settings. In 
terms of the WHO (2014a) recommendation of increased multisectoral integration 
among surveillance networks, there is an evident gap in South Asia. Increased national 
and regional efforts that imitate the WHO’s approaches of intersectoral collaboration 
(e.g. alignment with agricultural organizations) should be applied (WHO, 2014a). 
Furthermore, greater connection with the pharmaceutical industry in promoting AMR 
reduction would promote inclusive practice. Overall, the observed challenges in South 
Asia provide support for the WHO’s discussion of current surveillance gaps and the 
proposed recommendations should be followed. The primary lesson from South Asia is 
that ground-level action should be modified to suit the needs of relevant populations.  
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6.0   Conclusion and Recommendations 
 Global improvements in surveillance and monitoring have been stressed as one 
of the principle strategies to contain AMR, as seen in a number of WHO documents and 
the wider literature. More specifically, regular surveillance and monitoring of the use of 
antibiotics, general resistance patterns, and antibiotic sales are key aspects of 
examining the extent of the problem. In line with this, Byarugaba et al. (2010) assert that 
surveillance data should serve as an educational (rather than a marketing) tool for the 
introduction and utilization of new antibiotics. In other words, surveillance reports often 
influence physicians to utilize stronger drugs to combat increasing resistance 
(Byarugaba et al., 2010). The findings should instead promote discriminate antibiotic 
use as a way of addressing elevated AMR rates. Byarugaba et al. (2010) also suggest 
increased surveillance of pharmaceutical activities, specifically industry marketing 
tactics that may promote indiscriminate drug use (Appendix B; Table 3).  
 Strengthened surveillance should be accompanied by the development of 
guidelines and educational programs for rational antibiotic use (Tupasi, 1999). The 
WHO (2001) strategy for containing antimicrobial resistance outlines key areas of 
intervention, including: community education on infection transmission modes, 
prescriber education on antibiotic use, guidelines for antibiotic use, development of 
infection control programs, monitoring hospital antibiotic use, support for microbiology 
laboratories, development of governmental task force projects for special concerns, and 
international collaboration. For example, the Alliance for the Prudent Use of Antibiotics 
(APUA) is a collaborative initiative that creates a common platform for international 
surveillance practices. The APUA performs several functions, some of which include: 
raising awareness, knowledge sharing, promoting research and multidisciplinary 
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interventions, providing comprehensive solutions, incorporating feedback for global 
planning purposes, and encouraging international networking (Byarugaba et al., 2010).  
Future goals must build on current successes in terms of AMR surveillance and 
management. For example, Dineshkumar et al. (1995) illustrate the success of several 
institutions in India that have improved awareness and practice with regards to defining 
and measuring AMR burden. Working groups that aid with scientific/technical 
advancements, as well as broader analysis of the socioeconomic determinants of AMR, 
will also be beneficial (WHO, 2013). Overall, it is clear from the evidence presented in 
this capstone that although the issue of AMR is widespread, strategies to contain it are 
not. There is an unequal balance of emphasis on the issue, depending on geographic 
regions and context-dependent factors. In order to harmonize public health practices in 
South Asia and on a global scale, AMR needs to be a central public health priority. This 
can be addressed through the development of robust, comprehensive, and uniform 
surveillance systems that can detect AMR burden and increase understanding of the 
issue, especially within LMICs. Recommendations for the future should fall within the 
following broad domains: knowledge, support, and collective action.  
     Knowledge 
 On a broader systems level, detailed analysis and evaluation of prescription 
practices, treatment regimens (e.g. determining antibiotic dosage), and dispensing 
behaviours within developing nations, in combination with meticulous vigilance to other 
contributing factors, will prove useful for mitigating AMR. As an example, Kotwani et al. 
(2012) suggest the inclusion of pharmacists as partners with the community to raise 
awareness and promote rational antibiotic use. A multidisciplinary framework that 
targets a multitude of sectors, as well as the recruitment of motivated stakeholders, are 
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also key for improving knowledge on AMR (Kotwani et al., 2012). Improved surveillance 
would provide the data needed to conduct such analyses. In line with this, advancement 
of research and development on a global scale through increased funding can unlock 
valuable knowledge and provide innovative and practicable solutions.  
It is clear from the evidence that antibiotic use is closely linked to the 
development of AMR. In addition to promoting increased knowledge on a systems level, 
individual knowledge is crucial for changing consumption patterns and contextual 
behaviours. In terms of both local and global considerations, one future measure that 
can be taken is to prevent antibiotic misuse through increased training of healthcare 
professionals, especially within resource-limited settings. Through increased knowledge 
and awareness about the nature of antibiotics and drug-resistant bacteria, providers can 
take more precautionary measures when prescribing antibiotics to the general 
population. In line with this, medical curriculum in these countries should include 
education on pharmacotherapy and the promotion of evidence-based prescribing 
practices (De Vries et al., 1995; Vollebbregt et al., 2006). Bhutta and Vitry (1997) have 
asserted that pharmaceutical motives often fuel irrational use of antibiotics in medical 
settings; continuing education programs can serve as a buffer to combat these negative 
effects. Drlica and Perlin (2011) suggest that education for medical professionals should 
occur early on during their training. 
Knowledge in the form of educational programs for the public can also have a 
positive effect on changing common misconceptions about antibiotics and inducing 
subsequent behaviour change. The principles for antibiotic use need to be better taught 
(Sharma et al., 2005). Additionally, the harmful consequences of noncompliance with 
prescription regimens and other forms of improper use can be enforced through these 
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educational programs (Drlica and Perlin, 2011). They can also promote a change in 
perspective about antibiotic use as a method to treat all types of infections, which is a 
visible challenge in developing settings. Public education is an affordable strategy that 
can be achieved through greater use of the media and literature. Other strategies 
include focus groups, workshops, large-scale seminars, and the use of informational 
pamphlets in order to reduce unreasonable use. Radyowijati and Haak (2003) suggest 
exploring the ‘socio-cultural rationality’ of antibiotic use through these interventions. 
Similarly, Laxminarayan et al. (2013) emphasize the importance of addressing social 
norms in order to ensure future success. Alliances with civil society organizations are 
also crucial for improving the situation (Nweneka et al., 2009).  
Educational programs should also be targeted towards drug dispensers and 
those in pharmaceutical positions. In terms of health care provision, Wilkins et al. (2008) 
assert the usefulness of performance analysis through enhanced health information 
systems; this would aid with tracking and managing antibiotic use. Surveillance systems 
should function as a guide for antibiotic use in developing countries so that AMR can be 
mitigated and the effectiveness of current drugs maintained. Brusaferro et al. (2006) 
point to the benefits of focused inflection control programs in developing country 
hospitals. Patient indicators that give the most useful and relevant information should be 
selected to paint a picture of local conditions and inform interventions, from the 
perspective of surveillance studies (Brusaferro et al., 2006). These strategies at large 
will be useful downstream supplements to improved surveillance systems in developing 
countries. In line with this, Okeke et al. (2005b) suggest the implementation of pilot 
programs in advance of large-scale intervention to ensure the success of such efforts.  
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     Support 
A lack of support, whether financial, supervisory, or scientific, has rendered it 
difficult to analyze the precise causes of AMR in developing countries. Through a 
community-based approach to facing the issue of antimicrobial resistance, it can be 
ensured that multiple contributing factors are addressed. Competence of healthcare 
providers, within the larger goal of health systems strengthening, is a key component of 
change in relation to this issue. These actions can be performed with the help of aid 
(e.g. monetary funding, other resources) from relevant stakeholders. Utilizing increased 
funding for enforcement of laws pertaining to antibiotic sales will also prove beneficial. 
Support in the form of the sustainable provision of resources can have many 
positive consequences in terms of AMR surveillance. Simply, an increase in resources 
can lead to an increase in AMR information that is usable for informative interventions. 
Resources must be used in the most cost-effective way to combat the issue of AMR in 
developing countries. With increased capacity for conducting more appropriate and 
effective monitoring of AMR in laboratory settings, for example, countries can 
adequately equip themselves with the knowledge required to develop and implement 
strong surveillance systems. As Planta (2007) discusses, socioeconomic factors such 
as poverty affect the emergence and spread of AMR in developing countries; improved 
conditions would provide the necessary resources for effective surveillance systems. 
These changes can serve as mechanisms for augmenting local research capabilities.  
Increased funding on a global scale can ensure that applicable technologies and 
personnel are available to conduct the extensive surveillance work. This would also 
alleviate the issue of bias in the results due to limited agencies providing the funding for 
surveillance work. A key recommendation in this regard would be for countries to 
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develop national-level surveillance systems that align with the WHO global-level data 
repositories. On a national level, AMR-specific surveillance systems would aid with 
overall standardization, comparability, coordination, and harmonization. Accessibility 
and usability of these surveillance systems is crucial for developing world contexts. 
With regards to the need for technological advancement, the WHONET software 
is a free electronic tool for AMR surveillance that is already being utilized in many parts 
of the world (Stelling & O’Brien, 1997). WHONET exemplifies a robust surveillance 
system as it has built-in quality control functions that can identify laboratory errors and 
can be customized for specific purposes (clinical, epidemiological, veterinary, molecular, 
pharmacological, infection control, etc.) (Byarugaba et al., 2010). Furthermore, 
WHONET can utilize an array of graphic representations to analyze susceptibility 
patterns and has guidelines for interpretation of various methodologies for testing 
(Byarugaba et al., 2010). Other prominent features include its compatibility with global 
software systems (e.g. through provision of common codes/universal file formats for 
data storage) and its flexibility with data representation (Byarugaba et al., 2010; Sharma 
& Grover, 2004; Stelling & O’Brien, 1997). WHONET serves as an important and unified 
platform for decision-making (e.g. guiding empiric treatment of infections) in order to 
enhance AMR surveillance and mitigate resistance. Countries can analyze their own 
data for more consistent monitoring of AMR and are able to comparatively share the 
information to support national and global surveillance (Stelling & O’Brien, 1997).  
If considering the South Asian region, WHONET is currently being utilized as a 
surveillance support mostly in India. Sharma and Grover (2004) emphasize expanded 
and continued use of WHONET within hospitals, for example, in order to assist with the 
formation of control measures (e.g. restrictive drug policies) through web-based data 
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sharing between networks. Additionally, Agarwal et al. (2009) analyze the benefits of 
utilizing WHONET within military hospitals as a more efficient way of accumulating data 
and collectively analyzing it to promote health policies and control measures. A potential 
limitation of applying this software would be that WHONET does not function as a 
comprehensive patient management system and thus susceptibility data may have to 
be separately/manually entered (e.g. if a patient management system already exists) 
(Agarwal et al., 2009). As such, Agarwal et al. (2009) suggest that surveillance systems 
be integrated with patient management systems in hospitals/laboratories in order to 
ensure future success and sustain manpower in developing countries. From the 
perspective of health systems strengthening as a tool for enhancing public health 
surveillance, increasing funding from global partners can aid progress (Nsubuga et al., 
2010). The Global Fund Against Tuberculosis, AIDS, and Malaria, for example, can 
increase its focus towards building sustainable surveillance systems (incorporating 
health systems strengthening) within developing countries (Nsubuga et al., 2010).  
In Nepal, Ghosh et al. (2013) recently documented the effects of initial WHONET 
use in the country to monitor and assess resistance among uropathogens. The study 
was conducted in order to promote the development of a surveillance network that 
would assist with AMR policy-making in Nepal and interact with the national public 
health laboratory in the country (Ghosh et al., 2013). Increased communication of 
resistance data at various levels of functioning is also considered by the authors; 
hospitals, communities, and clinicians are some stakeholders that would benefit from 
information sharing at the local level (Ghosh et al., 2013). Increased international use of 
WHONET will promote uniformity in data storage, ease of data sharing/comparability, 
and collaboration for establishing surveillance networks in other developing countries  
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(Ghosh et al., 2013).  
There are several countries in South Asia that are utilizing WHONET (over one 
hundred laboratories) but there is always room for improvement (Grundmann et al., 
2011). Currently, Pakistan and Sri Lanka each have singular laboratories that utilize 
WHONET, and Bangladesh is currently not utilizing it. Increased efforts to promote 
WHONET use in these countries should be an integral component of future 
interventions. Development of national systems in South Asia can be achieved through 
increased partnerships with international agencies and non-profit organizations. AMR 
surveillance on a regional level should also be more greatly prioritized for South Asia, 
as it remains the most under-addressed WHO region in this regard; regional activities 
have been proposed but hardly conducted (Grundmann et al., 2011). As such, future 
progress towards the establishment of regional surveillance networks is crucial. 
Grundmann et al. (2011) report that WHONET as a surveillance system is being 
applied in over one hundred countries on a global scale in order to support local and 
national surveillance; close to two thousand clinical, public health, food, and veterinary 
laboratories are utilizing the program. WHONET plays a central role in the national 
surveillance systems of most of these countries (Grundmann et al., 2011). In relation to 
this, pathogen-specific WHO-affiliated surveillance networks are currently operating in 
South Asia and on a global scale for disease-control programs that address malaria, 
tuberculosis, and gonorrhea, to name a few (Grundmann et al., 2011). Grundmann et al. 
(2011) also outline the existence of external quality assessments of these initiatives; 
assessments are occurring in all WHO regions and should be increasingly supported 
and incorporated within regional surveillance processes. As part of regional 
surveillance, greater focus on community-acquired infections is also necessary;  
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application of the WHONET software is mostly visible for hospital settings in India, for 
example (Ahmed et al., 2014).  
     Collective Action 
With respect to a broader scale of analysis, increased communication and 
collaboration in terms of understanding and addressing AMR in developing countries is 
greatly needed. Strengthened surveillance and monitoring responses can ensure that 
the development of AMR in a specific community and/or population is accurately, 
efficiently, and effectively detected. This, in turn, can ensure timeliness of appropriate 
prevention and treatment methods. Addressing informational gaps within local and 
national surveillance systems can improve the development of treatment guidelines and 
result in enhanced and informed decision-making. From a global perspective, this can 
result in positive implications for timely policy-making, programming planning, and other 
intervention initiatives for high levels of AMR. It has been stated that strong policies 
surrounding AMR surveillance would require effective antibiotic stewardship by relevant 
stakeholders, regular screening/auditing of the process, and continual changes that 
pertain to observable and time-oriented AMR trends (Byarugaba et al., 2010). Ensuring 
that the balance between access and excess in relation to antibiotic use is maintained 
will require effective feedback loops within LMIC health systems (Laxminarayan et al., 
2013). As such, resistance-driven policy changes must be accompanied by and result in 
practical and substantial changes in drug production, supply, and usage. 
Pertaining to the evidence presented in this capstone, health systems 
strengthening is crucial for ensuring that communities and countries are prepared with 
regards to AMR. With well-equipped and more knowledgeable health workers, AMR can 
play a prominent role in the practice of health professionals. Adopting a broader 
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systems thinking approach for this issue would further illuminate the gaps that exist with 
regards to AMR surveillance and monitoring. Through highlighting the numerous factors 
that inform the organization of health systems, complex relationships between the 
individual and society become more visible. This would be a key incentive to action in 
targeting the contributors to AMR within developing settings. Increased communication 
between institutional and community partners, as well as other varied stakeholders, 
would ensure that surveillance and monitoring of AMR is prioritized in South Asian 
countries. Specifically, profits attained through antibiotic sales/prescriptions need to be 
addressed and the motives and/or interests of patients, physicians, pharmacists, and 
the agricultural industry need to better aligned in order to produce change. 
Vernet et al. (2014) suggest the creation of a global road map that serves to 
enhance AMR surveillance in resource-constrained countries; development of a 
research agenda that focuses on existing surveillance networks and recommendations 
to unite them are also suggested (Appendix B: Table 7). In line with this, Grundmann 
(2014) provides a primer for the road map that would aid with the development of a 
global AMR surveillance system. Through prioritization of AMR surveillance on a global 
scale, the primer can aid with identifying/defining specific objectives, as well as the 
scale, scope, and structure of surveillance efforts (Grundmann, 2014). Common 
demands of relevant stakeholders, focused on future global surveillance, are grouped 
into three main subject areas by the author. More specifically, patient-, population-, and 
pathogen-centred surveillance objectives are outlined in relation to clinical, policy, and 
infection control demands, respectively (Grundmann, 2014). Improving clinical 
treatments and reducing indiscriminate prescribing are some objectives relevant to 
patients while raising awareness and advocating for more informed allocation of health 
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resources are important population-relevant objectives (Grundmann, 2014). Similarly, 
understanding transmission routes is a pathogen-centred surveillance objective, as 
outlined by Grundmann (2014). Some other important aspects to consider include the 
type of surveillance (population- or laboratory-based), funding sources (public, private, 
public-private partnerships), and the organizational structure (i.e. increased 
centralization of surveillance systems) (Grundmann, 2014).  
With regards to type of surveillance, the WHO (2002) asserts that sentinel 
surveillance which limits data collection to certain areas may be more beneficial for 
LMICs, as opposed to comprehensive surveillance that covers data on all cases of an 
infection. A general lack of longitudinal surveillance in these countries may favour such 
systems but national coordination is still the key measure for success. In such cases, 
quality can outweigh quantity through targeted approaches that ensure the reliability of 
surveillance data. Proper sample definitions and consistency between participating 
sentinel sites is crucial (WHO, 2002). As Chandrasekaran et al. (2006) illustrate, the 
Indian sentinel surveillance system in terms of HIV prevalence data consists mostly of 
unlinked and anonymous testing sites. Although sentinel surveillance is expanding in 
the area, large sample population-based studies of HIV prevalence have highlighted 
potential problems with sentinel estimation (Dandona et al., 2006), suggesting 
increased evaluation and coordination for these sites. Overall, a step-wise approach 
that incorporates international agreement will be useful in the development of targeted 
national strategies as well as a global surveillance system that operates on an 
international scale (Laxminarayan et al., 2013; Grundmann, 2014). The WHO (2002) 
also echoes the importance of analyzing existing surveillance systems in order to build 
upon available resources to conduct these types of surveillance activities in South Asia.  
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In essence, local surveillance programs should inform global AMR surveillance 
infrastructure. For example, the International Network for the Demographic Evaluation 
of Populations and Their Health in Under-Resourced Countries (INDEPTH) initiative 
currently utilizes surveillance sites in India and Bangladesh to monitor consumer-level 
drug use (Grundmann et al., 2011). These efforts can be expanded to other regions. 
Similar to the WHO, Vernet et al. (2004) also recommend the creation of a 
communication plan such that organizations and funding agencies can collaboratively 
operate on national, regional, and international levels. Action items must take 
precedence within policy proposals in order to implement direct and timely measures. A 
global monitoring system would warrant the inclusion of all aspects of AMR, relaying 
‘SMART’ objectives through specific targets and indicators, measurable progress, and 
the attainment of goals that are achievable, realistic, and time-oriented. Similarly, it is 
hoped that countries will adopt national action plans for AMR that are in tune with the 
WHO’s draft global action plan. 
O’Brien and Stelling (2011) propose a deeper examination of limitations in data 
availability and/or integration within AMR surveillance. In response to this, a multilevel 
and integrated system is required on a global scale; improvements in informatics and 
genomics (e.g. improved phenotypic discrimination) can enhance microbiological 
functions and reporting of AMR trends (O’Brien & Stelling, 2011). Increased 
participation, as part of multicenter networks, can integrate the diverse range of 
surveillance levels that globally exist. As part of this strategy, some other factors to 
consider when assessing surveillance systems include the type/extent of laboratory 
testing, inclusivity of reports, and sources of funding (O’Brien & Stelling, 2011). In line 
with this, Teodoro et al. (2011) propose the implementation of a transnational 
  
48
surveillance network that promotes integration between databases and provides real-
time and source-independent monitoring of AMR. Efforts such as these can be applied 
to the South Asian context as modes of assistance for addressing current gaps. 
From the perspective of public health practice, this review has provided key 
insights into current limitations in AMR-related research. The findings can form the basis 
for better data navigation and informational practice within public health. As a public 
health practitioner, this review has aided with the realization that there is still a lot of 
progress to be made within certain aspects of this field of practice. Agencies such as 
the WHO that are currently addressing these issues are providing good 
recommendations but there is always room for improvement. The bureaucratic nature of 
many public health organizations deems it challenging to translate recommendations 
into foreseeable interventions. For example, the WHO proposes a global surveillance 
system but sources of funding for such a project are not clearly stated (Reardon, 2014). 
These challenges faced by the public health domain have provided valuable lessons in 
terms of professional practice and ways to move forward. A balance of knowledge and 
practice, in addition to the necessity for critical research, are key aspects of learning 
that can be attributed to this literature review.  
Considering surveillance and monitoring through a professional practice lens, it 
remains evident that critical exploration of this process is necessary in order to produce 
fitting responses on both local and global scales. Greater transparency and more 
appropriate management of data is crucial for stronger surveillance systems that can 
better target and respond to AMR within vulnerable populations and settings. Needs-
driven research and international cooperation would also aid these processes. 
Increased homogeneity of surveillance practices is required for the developing world. As 
  
49
part of this strategy, more detailed examination of the ‘social landscapes’ of LMICs and 
how they interact with AMR can inform future decisions regarding surveillance system 
performance/sustainability. The gaps in knowledge for AMR surveillance that are 
outlined in this capstone should inform local and global population-based strategies and 
program planning on behalf of policy-makers. The use of knowledge, support, and 
collective action strategies can provide an effective framework for changes in attitudes, 
practices, and policies for AMR surveillance in South Asia and beyond (Appendix A; 
Fig. 1). Broader recognition of AMR as a public health emergency will underlie 
successful public health action. The solution lies in institutional change on a global 
scale. 
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Figure 1.   AMR Surveillance Systems: Framework for Action & Effect 
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Figure 2.   Factors Affecting Antibiotic Use 
 
Source: Byarugaba, D. K., Amabile-Cuevas, C. F., Hsueh, P. R., Kariuki, S., & Okeke, I. N.  
 (2010). Antimicrobial resistance in developing countries. Springer. 
 
 
Figure 3.   Determinants of Antimicrobial Resistance 
 
 
 
 
 
 
 
 
 
Source: Byarugaba, D. K., Amabile-Cuevas, C. F., Hsueh, P. R., Kariuki, S., & Okeke, I. N.  
 (2010). Antimicrobial resistance in developing countries. Springer. 
 Figure 4.   Global Data Levels – Antimicrobial Resistance 
Source: Reardon, S. (2014). Antibiotic resistance sweeping developing world. Nature, 509(7499), 141. 
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Figure 5.   Potential Infection Control Strategies in Hospital Settings 
 
 
Source: Ghafur, A., Mathai, D., Muruganathan, A., Jayalal, J. A., Kant, R., Chaudhary, D., ... & Parikh, P.  
 (2013). The Chennai Declaration: a roadmap to tackle the challenge of antimicrobial  
 resistance. Indian journal of cancer, 50(1), 71.
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Table 1.   Summary of Findings for Select South Asian Countries 
 
Country Key Findings Relevant to AMR Surveillance & Monitoring 
India ￿ High MDR-TB and MRSA rates ￿  difficulties in treatment include limited tr
infrastructure and a lack of coordination  
￿ High prevalence of cholera, E. coli, and Salmonella infections ￿  poor sani
a general lack of intervention  
￿ High annual incidence of typhoid ￿  contributing factors include uneven me
differences in health-seeking behaviours, and inappropriate antibiotic use 
￿ Greater surveillance of HIV drug resistance is urgently needed  
￿ Surveillance challenges ￿  obtaining pathogen isolates, varying pathogen 
sample size, non-representativeness, study design, data standardization, d
quality control, underreporting, a lack of a cohesive framework for data inte
￿ Antibiotic misuse and overuse are major concerns ￿  lack of knowledge an
perceptions, expectations, and satisfaction influence physicians’ prescribin
￿ Vast availability of counterfeit drugs demands stricter regulations ￿  abund
with varying dispensing practices and a lack of data on the behaviours of c
attendants negatively affect usage and AMR rates  
￿ Rise of corporate healthcare industry has affected resource allocation for s
insufficient use of public reporting methods and a lack of national intervent
 
￿ Some areas of intervention include addressing over-the-counter antibiotic 
antibiotic use, auditing of pharmaceutical services, medical training of phys
development of a national AMR policy  
Pakistan ￿ High rates of antibiotic dispensing, usually based on demand  
￿ Over-the-counter availability of drugs + sociocultural attitudes = self-medic
 ￿ Lack of training and the possible reliance of the population on drug dispens
advice leads to misuse/overuse  
￿ Antibiotic sales affect AMR rates in Pakistan  
￿ Similar infection profile as India (MDR-TB, E. coli, etc.) and similar surveilla
￿ Hospital use of antibiotics creates selective pressure ￿  inadequate diagno
infection control practices, a lack of policies, limited laboratory capacities (‘
gap’), and a lack of funds hinder AMR surveillance and containment  
Bangladesh ￿ A variety of prominent infections (e.g. cholera, shigellosis, pneumonia, gon
￿ Antibiotic use stemming from local pharmacies is high ￿  approximately 90
sold without a prescription in Bangladesh  
￿ Knowledge gaps exist within drug prescribing practices ￿  qualifications of
dispensers are often unclear  
￿ Substandard antibiotics can lead to serious health consequences  
￿ Lack of adherence in medicinal drug promotion (e.g. inaccurate information
are distributed to physicians) ￿  promote indiscriminate antibiotic use 
￿ Antibiotics are often prescribed/dispensed based on availability, raising con
accessibility and weak regulations 
￿ Similar surveillance challenges as other South Asian countries ￿  a lack of
negatively affects availability of quantifiable and comparable baseline AMR
Sri Lanka ￿ High rates of resistant typhoid, MRSA, shigellosis, and pneumonia infectio
￿ Dispensers within pharmacies are often limited in knowledge on antimicrob
pricing and sales often affect dispensing practices in favour of the medical 
￿ Pharmaceutical industry exerts a heavy influence on pharmacy attendants
sales representatives provide most of the knowledge to dispensers, creatin
antibiotic dispensing/use 
￿ A general lack of guidelines and/or policies for appropriate antibiotic use an
professionals, similar to other South Asian countries  
 ￿ Surveillance challenges resonate with those observed in other South Asian
Table 2.   Gaps in Resistance Data for Common Pathogens 
 
 
Source: World Health Organization. (2014a). Antimicrobial resistance: Global report on surveillance 2014. Retrieved from  
http://www.who.int/drugresistance/documents/surveillancereport/en/. 
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Table 3.   Challenges and Solutions for AMR in Developing Countries 
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Adapted from: Byarugaba, D. K., Amabile-Cuevas, C. F., Hsueh, P. R., Kariuki, S., & Okeke, I. N.  
           (2010). Antimicrobial resistance in developing countries. Springer. 
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Table 4.   WHO Strategies for AMR Containment 
 
Source: Okeke, I. N., Klugman, K. P., Bhutta, Z. A., Duse, A. G., Jenkins, P., O'Brien, T. F., ... &  
 Laxminarayan, R. (2005b). Antimicrobial resistance in developing countries. Part II: strategies for  
 containment. The Lancet infectious diseases,5(9), 568-580. 
 73
Table 5.   Surveillance Constraints and Improvements – Hospital Infections 
 
 
 
Source: Allegranzi, B., Nejad, S. B., Combescure, C., Graafmans, W., Attar, H., Donaldson, L., & Pittet, D. 
(2011). Burden of endemic health-care-associated infection in developing countries: systematic  
review and meta-analysis. The Lancet, 377(9761), 228-241. 
 
 
 
 
 
 
 
 
 Table 6.   Antimicrobial Resistance By Resource Limitation Level  
 
 
Source: DiazGranados, C. A., Cardo, D. M., & McGowan Jr., J. E. (2008). Antimicrobial resistance: international control stra
 limited-resource settings. International Journal of Antimicrobial Agents, 32(1), 1–9. doi:10.1016/j.ijantimicag.2008.0
 
 
 
 
 Table 7.   Recommendations for Improving AMR Surveillance in Under-Resourced Countries    
 
Source: Vernet, G., Mary, C., Altmann, D. M., Doumbo, O., Morpeth, S., Bhutta, Z. A., & Klugman, K. P. (2014). Surveillanc
 resistance in under-resourced countries. Emerging infectious diseases, 20(3), 434. 
 
   
